244 related articles for article (PubMed ID: 24884454)
21. Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, coprescription of methotrexate and prior TNF-alpha inhibitors exposure.
Solau-Gervais E; Prudhomme C; Philippe P; Duhamel A; Dupont-Créteur C; Legrand JL; Houvenagel E; Flipo RM
Joint Bone Spine; 2012 May; 79(3):281-4. PubMed ID: 21724444
[TBL] [Abstract][Full Text] [Related]
22. Patient and physician perception of the infusion process of the biologic agents abatacept, infliximab, and rituximab for the treatment of rheumatoid arthritis.
Yazici Y; McMorris BJ; Darkow T; Rosenblatt LC
Clin Exp Rheumatol; 2009; 27(6):907-13. PubMed ID: 20149304
[TBL] [Abstract][Full Text] [Related]
23. [Rituximab in rheumatoid arthritis: a systematic review of efficacy and safety].
Hernández-Cruz B; García-Arias M; Ariza Ariza R; Martín Mola E
Reumatol Clin; 2011; 7(5):314-22. PubMed ID: 21925447
[TBL] [Abstract][Full Text] [Related]
24. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.
Shergy WJ; Isern RA; Cooley DA; Harshbarger JL; Huffstutter JE; Hughes GM; Spencer-Smith EA; Goldman AL; Roth SH; Toder JS; Warner D; Quinn A; Keenan GF; Schaible TF;
J Rheumatol; 2002 Apr; 29(4):667-77. PubMed ID: 11950005
[TBL] [Abstract][Full Text] [Related]
25. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis.
Curtis JR; Yang S; Patkar NM; Chen L; Singh JA; Cannon GW; Mikuls TR; Delzell E; Saag KG; Safford MM; DuVall S; Alexander K; Napalkov P; Winthrop KL; Burton MJ; Kamauu A; Baddley JW
Arthritis Care Res (Hoboken); 2014 Jul; 66(7):990-7. PubMed ID: 24470378
[TBL] [Abstract][Full Text] [Related]
26. Safety of rituximab in rheumatoid arthritis patients with a history of severe or recurrent bacterial infection: observational study of 30 cases in everyday practice.
Toussirot E; Pertuiset E; Sordet C; Augé B; Wendling D; Pallot-Pradès B; Collet P; Lohse A; Balblanc JC
Joint Bone Spine; 2010 Mar; 77(2):142-5. PubMed ID: 20171921
[TBL] [Abstract][Full Text] [Related]
27. Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial.
Suh CH; Yoo DH; Berrocal Kasay A; Chalouhi El-Khouri E; Cons Molina FF; Shesternya P; Miranda P; Medina-Rodriguez FG; Wiland P; Jeka S; Chavez-Corrales J; Linde T; Hrycaj P; Abello-Banfi M; Hospodarskyy I; Jaworski J; Piotrowski M; Brzosko M; Krogulec M; Shevchuk S; Calvo A; Andersone D; Park W; Shim SC; Lee SJ; Lee SY
BioDrugs; 2019 Feb; 33(1):79-91. PubMed ID: 30719632
[TBL] [Abstract][Full Text] [Related]
28. Rituximab in rheumatoid arthritis and the risk of malignancies: report from a French cohort.
Slimani S; Lukas C; Combe B; Morel J
Joint Bone Spine; 2011 Oct; 78(5):484-7. PubMed ID: 21196130
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR).
Rubbert-Roth A; Tak PP; Zerbini C; Tremblay JL; Carreño L; Armstrong G; Collinson N; Shaw TM;
Rheumatology (Oxford); 2010 Sep; 49(9):1683-93. PubMed ID: 20463186
[TBL] [Abstract][Full Text] [Related]
30. Incidence of new-onset and flare of preexisting psoriasis during rituximab therapy for rheumatoid arthritis: data from the French AIR registry.
Thomas L; Canoui-Poitrine F; Gottenberg JE; Economu-Dubosc A; Medkour F; Chevalier X; Bastuji-Garin S; Le Louët H; Farrenq V; Claudepierre P
J Rheumatol; 2012 May; 39(5):893-8. PubMed ID: 22505694
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
Higashida J; Wun T; Schmidt S; Naguwa SM; Tuscano JM
J Rheumatol; 2005 Nov; 32(11):2109-15. PubMed ID: 16265687
[TBL] [Abstract][Full Text] [Related]
32. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.
Mayer L; Kappos L; Racke MK; Rammohan K; Traboulsee A; Hauser SL; Julian L; Köndgen H; Li C; Napieralski J; Zheng H; Wolinsky JS
Mult Scler Relat Disord; 2019 May; 30():236-243. PubMed ID: 30844611
[TBL] [Abstract][Full Text] [Related]
33. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials.
van Vollenhoven RF; Emery P; Bingham CO; Keystone EC; Fleischmann R; Furst DE; Macey K; Sweetser M; Kelman A; Rao R
J Rheumatol; 2010 Mar; 37(3):558-67. PubMed ID: 20110520
[TBL] [Abstract][Full Text] [Related]
34. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE.
Tak PP; Rigby W; Rubbert-Roth A; Peterfy C; van Vollenhoven RF; Stohl W; Healy E; Hessey E; Reynard M; Shaw T
Ann Rheum Dis; 2012 Mar; 71(3):351-7. PubMed ID: 22012969
[TBL] [Abstract][Full Text] [Related]
35. Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis.
Mishra R; Singh V; Pritchard CH
Rheumatol Int; 2011 Apr; 31(4):481-4. PubMed ID: 20091035
[TBL] [Abstract][Full Text] [Related]
36. Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data.
Salmon JH; Perotin JM; Morel J; Dramé M; Cantagrel A; Ziegler LE; Ravaud P; Sibilia J; Pane I; Mariette X; Gottenberg JE;
Rheumatology (Oxford); 2018 Jan; 57(1):134-139. PubMed ID: 29069471
[TBL] [Abstract][Full Text] [Related]
37. Rituximab for the treatment of rheumatoid arthritis: an update.
Mok CC
Drug Des Devel Ther; 2013 Dec; 8():87-100. PubMed ID: 24403823
[TBL] [Abstract][Full Text] [Related]
38. Usefulness of power Doppler ultrasound for prediction of re-therapy with rituximab in rheumatoid arthritis: a prospective study of longstanding rheumatoid arthritis patients.
Reiche BE; Ohrndorf S; Feist E; Messerschmidt J; Burmester GR; Backhaus M
Arthritis Care Res (Hoboken); 2014 Feb; 66(2):204-16. PubMed ID: 23925935
[TBL] [Abstract][Full Text] [Related]
39. [Patient/rheumatologist evaluation of infusion treatment for rheumatoid arthritis].
Willeke P; Becker H; Wassenberg S; Pavenstädt H; Jacobi AM
Z Rheumatol; 2011 Apr; 70(3):232-4, 236-8. PubMed ID: 21359555
[TBL] [Abstract][Full Text] [Related]
40. [Safety of rituximab in patients with rheumatoid arthritis].
Morović-Vergles J
Reumatizam; 2010; 57(2):158-60. PubMed ID: 21875022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
